Based on the Inhibikase Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for Inhibikase Therapeutics Inc is USD 5.00 over the next 12 months. Inhibikase Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Inhibikase Therapeutics Inc is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Inhibikase Therapeutics Inc’s stock price was USD 2.23. Inhibikase Therapeutics Inc’s stock price has changed by -8.23% over the past week, -16.17% over the past month and -9.72% over the last year.
No recent analyst target price found for Inhibikase Therapeutics Inc
No recent average analyst rating found for Inhibikase Therapeutics Inc
Company Overview Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia. Read Less
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the tre...Read More
Frequently Asked Questions About Inhibikase Therapeutics Inc (IKT) Stock
Based on ratings from 1 analysts Inhibikase Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on IKT's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for IKT is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on IKT's stock to indicate if its overvalued.
The last closing price of IKT's stock was USD 2.23.
The most recent market capitalization for IKT is USD 0.16B.
Based on targets from 1 analysts, the average taret price for IKT is projected at USD 5.00 over the next 12 months.
This means that IKT's stock price may go up by +124.22% over the next 12 months.
We can't find any ETFs which contains Inhibikase Therapeutics Inc's stock.
As per our most recent records Inhibikase Therapeutics Inc has 8 Employees.
Inhibikase Therapeutics Inc's registered address is 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339.
You can get more information about it from Inhibikase Therapeutics Inc's website at https://www.inhibikase.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Inhibikase Therapeutics Inc (IKT) Stock
Based on ratings from 1 analysts Inhibikase Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on IKT's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for IKT is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on IKT's stock to indicate if its overvalued.
The last closing price of IKT's stock was USD 2.23.
The most recent market capitalization for IKT is USD 0.16B.
Based on targets from 1 analysts, the average taret price for IKT is projected at USD 5.00 over the next 12 months.
This means that IKT's stock price may go up by +124.22% over the next 12 months.
We can't find any ETFs which contains Inhibikase Therapeutics Inc's stock.
As per our most recent records Inhibikase Therapeutics Inc has 8 Employees.
Inhibikase Therapeutics Inc's registered address is 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339.
You can get more information about it from Inhibikase Therapeutics Inc's website at https://www.inhibikase.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IKT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
